Table 1. Comparison of patients within each eGFR stratum at week 4: $\geq$50 ml/min/1.73m^2 or 30-49 ml/min/1.73m^2

| Patients` characteristics | eGFR stratum: $\geq$50 ml/min/1.73m^2 | | p-value | eGFR stratum: 30-49 ml/min/1.73m^2 | | p-value |
	High-dose eplerenone N=742	High-dose placebo N=825		Low-dose eplerenone N=618	Low-dose placebo N=544	
Demographics						
Age (years)	67.7±7.3	67.7±7.4	NS	69.8±7.9	70.1±7.0	NS
Male gender, n (%)	579 (78%)	660 (80%)	NS	474 (77%)	409 (75%)	NS
BMI (Kg/m^2)	27.6±4.9	27.6±4.7	NS	27.4±5.0	27.4±5.0	NS
SBP (mmHg)	125±17	125±16	NS	123±18	122±17	NS
Heart rate (bpm)	74±16	73±15	NS	73±15	74±16	NS
Laboratory						
eGFR (ml/min/1.73m^2)	78±20	76±20	0.048	63±20	62±22	NS
Hemoglobin (g/dL)	13.9±1.5	13.9±1.6	NS	13.7±1.6	13.6±1.6	NS
Sodium (mmol/L)	140±4	140±4	NS	140±4	139±4	NS
Potassium (mmo/L)	4.2±0.4	4.3±0.4	<0.001	4.3±0.5	4.3±0.4	NS
Ecocardiography						
LVEF (%)	26±5	26±5	NS	26±5	26±5	NS
Co-morbidities						
Diabetes, n (%)	235 (32%)	225 (27%)	NS	222 (36%)	173 (32%)	NS
AFib, n (%)	221 (30%)	243 (30%)	NS	188 (30%)	189 (35%)	NS
Prior HFH, n (%)	365 (49%)	409 (50%)	NS	346 (56%)	313 (58%)	NS
Prior MI, n (%)	378 (51%)	414 (50%)	NS	352 (57%)	279 (51%)	NS
ICD/CRT, n (%)	133 (18%)	160 (19%)	NS	166 (27%)	150 (28%)	NS
Medications						
ACEi/ARB, n (%)	708 (95%)	784 (95%)	NS	589 (95%)	507 (93%)	NS
Beta-blocker, n (%)	661 (89%)	745 (90%)	NS	540 (87%)	468 (86%)	NS

Legend: BMI, body mass index; SBP; systolic blood pressure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; AFib, atrial fibrillation; MI, myocardial infarction; ICD/CRT; intracardiac defibrillator/cardiac resynchronization therapy; ACEi/ARB, angiotensin converting enzyme inhibitors/angiotensin receptor blocker.

Table 2. Mean eplerenone/placebo doses (in mg) within each eGFR stratum during the trial

eGFR strata	eGFR ≥50 ml/min/1.73m^2 stratum		eGFR 30-49 ml/min/1.73m^2 stratum	
Eplerenone/placebo dose (mg)	High-dose eplerenone	High-dose placebo	Low-dose eplerenone	Low-dose placebo
Study start	24.7±2.6	24.8±2.7	17.0±6.4	16.1±5.6
Week 4	38.9±13.2	40.4±12.7	23.4±9.6	23.3±9.8
Month 5	42.0±12.3	43.6±11.2	24.8±10.8	27.3±11.6
Month 12	42.3±12.4	43.9±11.1	26.8±12.3	30.2±12.6
Month 24	41.6±12.5	43.7±11.3	28.0±11.2	30.8±12.7
Study end	39.8±13.3	41.8±12.3	24.6±11.6	26.3±12.7

Table 3. Adjusted hazard ratio of within each eGFR strata

Study outcomes	eGFR ≥50 ml/min/1.73m^2 stratum: High-dose eplerenone vs. placebo					eGFR 30-49 ml/min/1.73m^2 stratum: Low-dose eplerenone vs. placebo					P for interaction
	Event (%) Eplerenone	Event (%) Placebo	ARD (%)	HR (95%CI)*	p-value	Event (%) Eplerenone	Event (%) Placebo	ARD (%)	HR (95%CI)*	p-value	
HFH/CVM	100 (13.5)	178 (21.6)	-8.1	0.58 (0.45-0.74)	<0.001	149 (24.1)	177 (32.5)	-8.4	0.62 (0.49-0.78)	<0.001	0.89
CVM	51 (6.9)	89 (10.8)	-3.9	0.61 (0.43-0.86)	0.004	96 (15.5)	95 (17.5)	-1.9	0.77 (0.58-1.04)	0.084	
HFH**	69 (9.3)	126 (15.3)	-6.0	0.56 (0.42-0.76)	<0.001	95 (15.4)	127 (23.3)	-8.0	0.55 (0.41-0.72)	<0.001	

*Model adjusted on age (75+ vs. <75 y), gender (male vs. female), systolic blood pressure (<130 vs. 130+ mmHg), heart rate (<80 vs. 80+ bpm), diabetes (yes vs, no), hemoglobin (<11 vs. 11-12.9 vs. 13+ g/dL), prior HFH (yes vs. no), eGFR (<60 vs. 60+ ml/min/1.73m^2), prior MI/CABG (yes vs. no), BMI (<25 vs. 25+ Kg/m^2). Note: unadjusted models provide similar results.

**Rate Ratio including repeated events.

Legend: HFH, hospitalization for heart failure; CVM, cardiovascular mortality; ARD, absolute risk difference; HR, hazard ratio.

Table 4. Investigator reported adverse events (AEs) by allocation dose

Adverse event (AE)	eGFR ≥50 ml/min/1.73m^2 stratum			eGFR 30-49 ml/min/1.73m^2 stratum			p-value high vs. low eplerenone	p-value high vs. low placebo
	High-dose eplerenone	High-dose placebo	p-value	Low-dose eplerenone	Low-dose placebo	p-value		
Hyperkalemia	27 (3.6%)	11 (1.3%)	0.005	82 (13.3%)	39 (7.2%)	<0.001	<0.001	<0.001
Hypokalemia	5 (0.7%)	18 (2.2%)	0.018	11 (1.8%)	12 (2.2%)	0.68	0.064	1
Renal failure	9 (1.2%)	14 (1.7%)	0.53	29 (4.7%)	27 (5.0%)	0.89	<0.001	0.001
AE drug discontinuation	74 (10.0%)	108 (13.1%)	0.058	114 (18.4%)	114 (21.0%)	0.30	<0.001	<0.001